Multiple System Atrophy, Pain Threshold
Conditions
Keywords
subjective pain, Multiple System Atrophy
Brief summary
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder. MSA is dominated by autonomic/urogenital failure which may be associated with either Parkinsonism (MSA-P subtype) or with cerebellar ataxia (MSA-C subtype). The prognostic of this disease is bad because it ended with the patient's death few years later. No neuroprotective treatment has shown a real efficacy. 50% of patients suffering of MSA frequently experienced painful sensation. The origin of this pain is unknown. In Parkinson disease (PD) ; arguments suggest the implication of dopamine neuromediator pathway in integration and modulation of pain. Several studies suggest the existence of various influences with dopamine implication in the appearance of painful sensation and that would be inhibitory. That's why observed painful symptoms in MSA and PD could be due to a decrease of pain appearance threshold, secondary to a lost of control of sensitizes centres, to Parkinson control. It is interesting to determine if MSA as PD is responsible for a decrease of pain threshold and to characterise the levodopa effect on the patient's pain threshold. Better physiopathology knowledge of pain in MSA is necessary to improve the therapeutic care. Because the efficacy of others treatments is low, it's important to improve the research for a better comfort of patients with a better understanding, analysing and treating of the pain.
Interventions
DRUGLevodopa test
Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
PROCEDUREdetermination of objective and subjective pain threshold
Test without levodopa intake
Sponsors
University Hospital, Toulouse
Fondation de France
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients from 50 to 80 years old (Male and female) * Patients suffering of a diagnosis possible or probable MSA-P with the international criteria (2008). * Patients with clinical diagnosis of Parkinson's disease according to the criteria of the UKPDSBB (Gibb et Lees, 1988; Hughes et al, 1992) * Patients with no cognitive troubles * Patients who give their informed and signed consent. * Patients affiliated to a social protection program
Exclusion criteria
* Patient suffering from an other parkinson syndrome than MSA and PD, by example progressive supranuclear palsy, corticobasal degeneration… * Patient suffering of a diagnosis possible or probable MSA-C with the international criteria * Patient suffering from another pathology causing chronic pain (rheumatic disease, traumatic or orthopedic pathologies…) * Patient under tutelage, curatella or law protection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Subjective pain threshold | 60 minutes | Subjective pain threshold determined using thermal stimulation (Thermotest) with the method of levels, before and after levodopa intake for MSA patients and PD patients and once for healthy volunteers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective nociceptive pain threshold | 15 minutes | Objective nociceptive pain threshold thanks to reflex of flexion (reflex RIII)before and after levodopa intake for MSA patients and PD patients and once for healthy volunteers |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORChristine Brefel-Courbon, MD
University Hospital, Toulouse
Outcome results
None listed